Application of platform process development approaches to the manufacturing of Mabcalin™ bispecifics

The PD-L1/4-1BB bispecific Antibody-Anticalin fusion protein PRS-344/S095012 elicits strong T-cell stimulation in a tumor-localized manner

(2022) Janet K. Peper-Gabriel et al.   CLINICAL CANCER RESEARCH

“HIGH‐RISK” HOST CELL PROTEINS (HCPs): A MULTI‐COMPANY COLLABORATIVE VIEW

(2021) Marisa Jones et al.   BIOTECHNOLOGY AND BIOENGINEERING

Quantitative N-Glycan Profiling of Therapeutic Monoclonal Antibodies Performed by Middle-Up Level HILIC-HRMS Analysis

(2021) Bastiaan L. Duivelshof et al.   Pharmaceutics

A potential downstream platform approach for WuXiBody-based IgG-like bispecific antibodies

(2020) Gaili Guo et al.   PROTEIN EXPRESSION AND PURIFICATION

Tumor-localized costimulatory T cell engagement by the 4-1BB/HER2 bispecific antibody-Anticalin fusion PRS-343

(2019) Marlon J Hinner et al.   CLINICAL CANCER RESEARCH

Anticalin® Proteins as Therapeutic Agents in Human Diseases

(2018) Christine Rothe et al.   BIODRUGS

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

(2018) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

An Integrated Approach to Aggregate Control for Therapeutic Bispecific Antibodies Using an Improved Three Column Mab Platform-Like Purification Process

(2018) Cassia Andrade et al.   BIOTECHNOLOGY PROGRESS

Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab

(2018) Yan Li et al.   Cell Reports

Evidence for intermolecular domain exchange in the Fab domains of dimer and oligomers of an IgG1 monoclonal antibody

(2017) Yin Luo et al.   mAbs

4-1BB–Enhanced Expansion of CD8 + TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8 + T Cells

(2017) Michiko Harao et al.   Cancer Immunology Research

Cell culture media impact on drug product solution stability

(2016) Jennifer L. Purdie et al.   BIOTECHNOLOGY PROGRESS

Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity

(2016) Andrew D. Tustian et al.   mAbs

The Menagerie of Human Lipocalins: A Natural Protein Scaffold for Molecular Recognition of Physiological Compounds

(2015) André Schiefner et al.   ACCOUNTS OF CHEMICAL RESEARCH

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies

(2012) Christian Klein et al.   mAbs

Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains

(2011) Jürgen Schanzer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative metabolite analysis to understand lactate metabolism shift in Chinese hamster ovary cell culture process

(2011) Jun Luo et al.   BIOTECHNOLOGY AND BIOENGINEERING

Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects

(2010) Kannan Gunasekaran et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

(2010) Jennifer S. Michaelson et al.   mAbs

Cell culture processes for monoclonal antibody production

(2010) Feng Li et al.   mAbs

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY

Recent advances in large-scale production of monoclonal antibodies and related proteins

(2010) Abhinav A. Shukla et al.   TRENDS IN BIOTECHNOLOGY

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Comparison of the ability of wild type and stabilized human IgG4 to undergo Fab arm exchange with endogenous IgG4 in vitro and in vivo

(2009) Kenneth B. Lewis et al.   MOLECULAR IMMUNOLOGY